CHEK2 and cancer: Larger datasets are needed to determine if all 3 LR variants have the same association with breast cancer risk when combined with a CHEK2 PV and if individuals with biallelic LR variants have no difference in their cancer risk phenotype from those with monoallelic LR variants or the general population, as our findings suggest.